Cel-Sci
CVMCEL-SCI Corporation is a late clinical-stage biotechnology company focused on developing immunotherapies that utilize the body's natural immune system to treat cancer and infectious diseases.
Table of contents
Earnings
Next report
Aug 17, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
CEL-SCI Corporation is a late clinical-stage biotechnology company focused on developing immunotherapies that utilize the body's natural immune system to treat cancer and infectious diseases. Its core value proposition centers on administering biological treatments as a first-line therapy before standard surgical or chemical interventions to maximize immune response. The company's lead candidate is designed to address significant unmet needs in head and neck cancer patients with specific biomarkers.
CEL-SCI is a late-stage clinical developer positioning its lead product as a unique neoadjuvant therapy for low PD-L1 expressing tumors, a segment underserved by current checkpoint inhibitors.
Questions, answered.
- What is Cel-Sci's market cap?
- Cel-Sci (CVM) has a market capitalization of $23.6M and trades on AMEX.
- Who are Cel-Sci's competitors?
- Cel-Sci's key competitors include Merck & Co., Bristol-Myers Squibb, ImmunityBio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Cel-Sci partner with?
- Cel-Sci's notable partners include Dallah Pharma, Teva Pharmaceutical Industries Ltd., Orient Europharma Co., Ltd., and others.
- Where is Cel-Sci headquartered?
- Cel-Sci is headquartered in United States of America and employs approximately 44 people. It has been publicly traded since 1983.